	US 12,479,921 B2
	Anti-PD-L1 antibody and use thereof
Bohua Li, Shanghai (CN); Huajing Wang, Shanghai (CN); and Xiaowen He, Shanghai (CN)
Assigned to Oricell Therapeutics Co., Ltd., Shanghai (CN)
Filed by Oricell Therapeutics Co., Ltd., Shanghai (CN)
Filed on Apr. 17, 2024, as Appl. No. 18/637,522.
Application 18/637,522 is a continuation of application No. 17/046,265, granted, now 11,993,655, previously published as PCT/CN2018/102584, filed on Aug. 27, 2018.
Claims priority of application No. 201810309302.5 (CN), filed on Apr. 9, 2018.
Prior Publication US 2024/0317863 A1, Sep. 26, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 31/713 (2006.01); A61P 35/00 (2006.01); C12N 5/10 (2006.01); C12N 15/63 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2827 (2013.01) [A61K 31/713 (2013.01); A61P 35/00 (2018.01); C07K 16/2878 (2013.01); C07K 16/2896 (2013.01); C12N 5/10 (2013.01); C12N 15/63 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01)]

12 Claims

1. An antibody or an antigen binding fragment thereof, which is capable of binding to CD137 protein, comprising a light chain variable region VL which comprises LCDR1-3 and a heavy chain variable region VH which comprises HCDR1-3, the amino acid sequences of said LCDR1-3 are sequentially set forth in SEQ ID NO: 80-82, and the amino acid sequences of said HCDR1-3 are sequentially set forth in SEQ ID NO: 77-79.